This report reviews a completed trial of the six minute pegboard ring test in Parkinson’s disease and its regulatory implications for device based assessment. The record is dated February 20 2026 and the primary sponsor is Sanko University. The study focuses on functional capacity and upper extremity function in Parkinson’s disease and aims to evaluate validity and safety. The excerpt provided does not include trial results in the text supplied here, so formal regulatory conclusions require access to the full data set.
What changed in the evidence base for the six minute pegboard ring test in Parkinson’s disease?
The ClinicalTrials.gov record NCT07422064 is listed as completed and attributes sponsorship to Sanko University. The record includes a link to the registry page for verification. The presence of a registry entry and a sponsor indicates formal study activity in a recognized venue. The trial focuses on functional capacity and upper extremity function and centers on validity and safety as key attributes for device based assessment. This indicates a regulatory oriented approach to validating a tool used for motor function in Parkinson’s disease.
The entry identifies the aims to evaluate functional capacity and upper extremity function while focusing on validity and safety. The plan suggests standardized procedures and endpoints that regulators expect for evidence of measurement integrity. The excerpt underscores a regulatory lens rather than a purely clinical narrative and frames the test within a framework of device evaluation and risk management.
The excerpt provided does not include trial results, so formal regulatory conclusions require access to full results. Without results the assessment remains speculative and relies on subsequent data sharing and peer reviewed publication. Regulators would look for clear descriptions of study design, populations, performance metrics and safety observations before accepting any claims about the test.
What is the six minute pegboard ring test?
The test measures upper extremity function and functional capacity by performing timed peg placement tasks on a pegboard ring device during a fixed period. The description in the record aligns with a goal of producing objective functional data that could be used alongside other assessments. The focus on validity and safety signals that any regulatory use would require robust performance data and clear risk management.
How could the results influence regulatory assessment of the test?
If validity and reliability are demonstrated in full results the pegboard ring test could inform regulatory evaluation of motor function measures used in Parkinson’s disease. The record signals a potential role for this test as part of a device based assessment framework subject to established performance criteria. Regulators typically require replication of results, demonstration of cross site reliability and clear documentation of risk controls. The proposal of a validated tool into a regulatory workflow would require standardized protocols and transparent data access for review.
Regulators expect robust evidence of reliability, consistency across sites and safety. The presence of a sponsor and trial completion suggests a move toward broader data dissemination that could support future labeling claims when appropriate. The text also implies a need for explicit statements from the manufacturer regarding intended use and performance claims which would be evaluated in a regulatory submission. The evidence would need to show how the test compares with existing measures and whether it adds unique value to the regulatory decision making process.
Any official statements about intended use and performance must come from the device manufacturer; the source text does not provide such statements. Until such statements are available reviewers should treat claims as prospective and rely on published results and evaluator notes for interpretation.
What safety considerations are relevant?
The study lists safety as a focus area but the provided excerpt does not supply safety results. Clinicians and regulators should require standardized administration and monitoring during testing to minimize risks for people with Parkinson’s disease. Safety checks should cover equipment conditions, participant readiness and protocol adherence to ensure consistent data collection.
- Risk management and protocol standardization are essential.
- Participant safety monitoring should be integrated into the test protocol.
- Results should report adverse events and severity levels.
FAQ
- 1. What does completed trial mean for regulatory use?
Answer: The record indicates completion and focus on validity and safety, but no full results are provided in the excerpt. Regulatory use requires access to complete results and formal analysis. - 2. Will results be published?
Answer: The source text does not specify publication timing; external sources or registry updates may provide information. - 3. How does this test compare to other measures?
Answer: The source text notes it is a functional capacity and upper extremity assessment with a focus on validity and safety, but it does not provide comparative data.
In summary the record confirms a completed study evaluating a six minute pegboard ring test for Parkinson’s disease with emphasis on validity and safety. Regulators will need access to full results to assess performance and risk.
This material is intended for professionals and is not legal advice. It does not replace regulatory guidance.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07422064?term=medical+device